Investigating the best glucocorticoid treatments for vocal fold disease
Molecular mechanisms underlying optimal glucocorticoid therapy for vocal fold disease
['FUNDING_R21'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-10840435
This study is looking at different types of medications called glucocorticoids to find out which ones can help heal vocal fold injuries by reducing inflammation and preventing scarring, so that people with voice problems can recover better.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10840435 on ClinicalTrials.gov |
What this research studies
This research aims to identify which glucocorticoids (GCs) can effectively balance anti-inflammatory and fibrotic gene expression in models of vocal fold injury. By studying how different types and concentrations of GCs affect gene expression in vocal fold fibroblasts, the researchers hope to determine the optimal treatment regimen. This could lead to improved healing outcomes for patients with vocal fold disease, reducing inflammation while preventing excessive scarring that can impair voice function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from vocal fold disease who may benefit from glucocorticoid therapy.
Not a fit: Patients with vocal fold disease who are not candidates for glucocorticoid treatment or those with other underlying conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for vocal fold disease, enhancing healing and preserving vocal function.
How similar studies have performed: Other research has shown promise in optimizing glucocorticoid therapies for various conditions, suggesting potential success for this approach in vocal fold disease.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GARABEDIAN, MICHAEL J. — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: GARABEDIAN, MICHAEL J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Communication Disorders, Communicative Disorders